POC

MERCURY SYSTEMS ALERT: Bragar Eagel & Squire, P.C. is Investigating Mercury Systems, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm

Retrieved on: 
Friday, February 16, 2024
CFO, Mercury Systems, Acquisition, Telephone, POC, News, Small business, GAAP, Accreditation, Mercury, Glass house, EPS, MRCY, P.C

Our investigation concerns whether the board of directors of Mercury Systems have breached their fiduciary duties to the company.

Key Points: 
  • Our investigation concerns whether the board of directors of Mercury Systems have breached their fiduciary duties to the company.
  • Mercury Systems is a technology company that produces component modules and subsystems for the aerospace and defense industries.
  • The Mercury Systems class action lawsuit further alleges that on July 26, 2022, Glasshouse Research initiated coverage of Mercury Systems with a strong sell report entitled “Roll-Up Mercury Systems Set to Unravel.” The Mercury Systems class action lawsuit alleges that on this news, the price of Mercury Systems common stock fell nearly 8%.
  • The Mercury Systems class action lawsuit alleges that on this news, the price of Mercury Systems common stock fell nearly 10%.

Poxel Reports Cash and Revenue for the Full Year 2023 and Provides Corporate Update

Retrieved on: 
Thursday, February 15, 2024
Science, Other Science, Biotechnology, Research, Pharmaceutical, Health, Clinical Trials, Other Health, Merck, Kidney, USD, POC, Adrenoleukodystrophy, Merck Serono, EPO, JPY, AMN, Sumitomo Pharma, European Patent Convention, Safety, Biomarker, EUR, ALD, ADPKD, Serono, Adenosine, Pharmacokinetics, Patent, Fatty liver disease, Patient, Diabetes, Disease, NASH, Plasma, Male, DSM-IV codes, VLCFA, Pharmaceutical industry

Thomas Kuhn, Chief Executive Officer of Poxel, stated: “We remain focused and continue to concentrate all our efforts at securing financing options, prioritizing non-dilutive solution, and partnerships.

Key Points: 
  • Thomas Kuhn, Chief Executive Officer of Poxel, stated: “We remain focused and continue to concentrate all our efforts at securing financing options, prioritizing non-dilutive solution, and partnerships.
  • We’ve also progressed our advanced discussions – in some cases on an exclusive basis – with several potential partners for each of our three proprietary products.
  • Based on this conservative assumption, Poxel expects to receive 8% royalties on TWYMEEG® net sales.
  • As of December 31, 2023, total cash and cash equivalents were EUR 2.3 million (USD 2.6 million)1, as compared to EUR 13.1 million (USD 14.0 million) as of December 31, 2022.

Absolut Empire's Ball Returns for Season 5 with Nine Houses Competing to Be Canada's Next Drag Empire

Retrieved on: 
Thursday, February 15, 2024
Devery, Destiny, Capital Pride, Individual, Ball, POC, Star, Haus, The Great Hall, Sound, House, Masculinity, Creativity, Absolut Vodka, Lighting, Heart, El Mocambo

Founded by Scarlett BoBo, Absolut Empire's Ball celebrates the dazzling artistry and creativity of drag in all its fabulous forms!

Key Points: 
  • Founded by Scarlett BoBo, Absolut Empire's Ball celebrates the dazzling artistry and creativity of drag in all its fabulous forms!
  • Now in its fifth season, Absolut Empires Ball will have nine lucky houses compete from March through May, judged by some of the best in the business, including Manny Dingo, Lizzie Renaud, Alyssin Chaynes and Mojo Toronto.
  • This competition offers drag houses the chance of a lifetime to mesmerize large audiences with top-notch, professional productions.
  • From breathtaking stage setups to stunning lighting and sound, Absolut Empire's Ball creates an unforgettable experience for both performers and spectators.

PoC Launched to Test Smart-charging Service Using EV Connected Technologies

Retrieved on: 
Thursday, February 15, 2024
EV, PHEV, POC, Outlander, Mitsubishi Motors, Mitsubishi Corporation, Mitsubishi Group, Smartphone, Environment

This PoC will seek to verify the commercial viability of what would be Japan's first smart-charging service leveraging EV connected technologies.

Key Points: 
  • This PoC will seek to verify the commercial viability of what would be Japan's first smart-charging service leveraging EV connected technologies.
  • *Kaluza is a subsidiary of the UK-based innovative energy service provider OVO Group, in which MC acquired a 20% interest in 2019.
  • During the PoC period, customers will subscribe to a charging plan that has been specially developed by MC Retail Energy exclusively for this service.
  • Furthermore, because this service will make it possible to directly control EV charging from Kaluza's platform via Mitsubishi Motors' connected systems, it does not require any communications-capable (i.e.

Autonomix Medical, Inc. Reports Third Quarter FY2024 Financial Results and Reiterates Upcoming Key Milestones

Retrieved on: 
Wednesday, February 14, 2024
Engineering, Ethics committee, Nervous system, Research, POC, AMIX, Collateral damage, Marketing, Quality of life, Pain, Calendar, Ethics, IPO, Advertising, Launch, Completeness, Patient, Clinical trial, Disease, Pancreatic cancer, Trial of the century, Ethanol, Medical imaging

THE WOODLANDS, TX, Feb. 14, 2024 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company focused on advancing innovative technologies to revolutionize how diseases involving the nervous system are diagnosed and treated, reported financial results yesterday for the third quarter FY2024 ended December 31, 2023 and provided a corporate update.

Key Points: 
  • “I am incredibly pleased with the progress we have made on the corporate, financial and clinical fronts in such a short period of time.
  • We are grateful for the continued support and remain focused on successfully executing on the milestones laid out ahead of us,” commented Lori Bisson, Chief Executive Officer of Autonomix.
  • Achieving “proof-of-concept” in this area could open the door to blockbuster diseases, expanding the horizons for the Company’s technology.
  • Summary of Financial Results for Q3 FY2024 Ended December 31, 2023
    For the nine months ended December 31, 2023 and 2022, the Company incurred net losses of $10.0 million and $1.3 million, respectively.

DEADLINE ALERT for MRCY and ON: The Law Offices of Frank R. Cruz Reminds Investors of Class Actions on Behalf of Shareholders

Retrieved on: 
Monday, February 12, 2024
Suite, Investment, POC, Small business, Acquisition, Onsemi, Law, Accreditation, Mercury, Defendant, Security (finance)

LOS ANGELES, Feb. 12, 2024 (GLOBE NEWSWIRE) -- The Law Offices of Frank R. Cruz reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies.

Key Points: 
  • LOS ANGELES, Feb. 12, 2024 (GLOBE NEWSWIRE) -- The Law Offices of Frank R. Cruz reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies.
  • Investors have until the deadlines listed below to file a lead plaintiff motion.
  • Investors suffering losses on their investments are encouraged to contact The Law Offices of Frank R. Cruz to discuss their legal rights in these class actions at 310-914-5007 or by email to [email protected] .
  • The Law Offices of Frank R. Cruz, Los Angeles

binx health Enters into National Distribution Agreement with Cardinal Health to Increase Access to the CLIA-waived, FDA-cleared binx io

Retrieved on: 
Monday, February 12, 2024
Cardinal, Hospital, POC, FDA, Infection, Female, Pharmacy, Cardinal Health, Emergency, World Congress, Patient, CLIA, Diagnosis, Male, Gonorrhea, Chlamydia, STI, Medical imaging

Collaborating with Cardinal Health provides binx health with additional access to the acute clinical care settings via its vast sales network in the market.

Key Points: 
  • Collaborating with Cardinal Health provides binx health with additional access to the acute clinical care settings via its vast sales network in the market.
  • We are proud that we have earned their trust in binx and the binx io," said Jeffrey Luber, binx health’s Chief Executive Officer.
  • With this distribution collaboration, together binx health and Cardinal Health teams will help improve access to the treatment of CT/NG.
  • For more information about the binx io, visit mybinxhealth.com/binx-io or contact your Cardinal Health representative.

Alys Pharmaceuticals launches with $100M financing from Medicxi to advance Immuno-Dermatology focused pipeline

Retrieved on: 
Monday, February 12, 2024
Cancer, Cutaneous T-cell lymphoma, Research, Skin, POC, University of Massachusetts, Atopic dermatitis, Inflammation, Gustave Roussy, Vitiligo, Mastocytosis, Partner, Peptide, Alopecia areata, Therapy, Patient, Small RNA, LMU, Georgia Tech, Nobel Prize, Pharmaceutical industry

BOSTON and GENEVA, Switzerland, Feb. 12, 2024 /PRNewswire/ -- Alys Pharmaceuticals, Inc. ("Alys"), an immuno-dermatology focused company, launches today with an R&D pipeline enabled by multiple platform technologies and a $100 million financing by Medicxi.

Key Points: 
  • BOSTON and GENEVA, Switzerland, Feb. 12, 2024 /PRNewswire/ -- Alys Pharmaceuticals, Inc. ("Alys"), an immuno-dermatology focused company, launches today with an R&D pipeline enabled by multiple platform technologies and a $100 million financing by Medicxi.
  • Originating from the aggregation of six asset-centric Medicxi companies, Alys boasts a robust pipeline of innovative programs and platforms targeting multiple dermatological indications.
  • The pipeline also includes programs focused on underserved indications such as mastocytosis, cutaneous T-cell lymphoma or prevention of skin side effects of oncology therapies.
  • Alys combines the assets and platforms of Aldena Therapeutics, Graegis Pharmaceuticals, Granular Therapeutics, Klirna Biotech, Nira Biosciences and Vimela Therapeutics.

Alys Pharmaceuticals launches with $100M financing from Medicxi to advance Immuno-Dermatology focused pipeline

Retrieved on: 
Monday, February 12, 2024
Cancer, Cutaneous T-cell lymphoma, Research, Skin, POC, University of Massachusetts, Atopic dermatitis, Inflammation, Gustave Roussy, Vitiligo, Mastocytosis, Partner, Peptide, Alopecia areata, Therapy, Patient, Small RNA, LMU, Georgia Tech, Nobel Prize, Pharmaceutical industry

BOSTON and GENEVA, Switzerland, Feb. 12, 2024 /PRNewswire/ -- Alys Pharmaceuticals, Inc. ("Alys"), an immuno-dermatology focused company, launches today with an R&D pipeline enabled by multiple platform technologies and a $100 million financing by Medicxi.

Key Points: 
  • BOSTON and GENEVA, Switzerland, Feb. 12, 2024 /PRNewswire/ -- Alys Pharmaceuticals, Inc. ("Alys"), an immuno-dermatology focused company, launches today with an R&D pipeline enabled by multiple platform technologies and a $100 million financing by Medicxi.
  • Originating from the aggregation of six asset-centric Medicxi companies, Alys boasts a robust pipeline of innovative programs and platforms targeting multiple dermatological indications.
  • The pipeline also includes programs focused on underserved indications such as mastocytosis, cutaneous T-cell lymphoma or prevention of skin side effects of oncology therapies.
  • Alys combines the assets and platforms of Aldena Therapeutics, Graegis Pharmaceuticals, Granular Therapeutics, Klirna Biotech, Nira Biosciences and Vimela Therapeutics.

MRCY DEADLINE TOMORROW: ROSEN, TOP RANKED GLOBAL COUNSEL, Encourages Mercury Systems, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important February 12 Deadline in Securities Class Action - MRCY

Retrieved on: 
Sunday, February 11, 2024
Titan, Mercury Systems, Acquisition, Court, POC, Class, Plaintiff, Advertising, Accreditation, Mercury, MRCY, Tobacco

WHAT TO DO NEXT: To join the Mercury class action, go to https://rosenlegal.com/submit-form/?case_id=21166 or call Phillip Kim, Esq.

Key Points: 
  • WHAT TO DO NEXT: To join the Mercury class action, go to https://rosenlegal.com/submit-form/?case_id=21166 or call Phillip Kim, Esq.
  • If you wish to serve as lead plaintiff, you must move the Court no later than February 12, 2024.
  • The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation.
  • 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017.